AAAAAA
Results: 1-25/37
Authors:
KALOW W
TANG BK
ENDRENYI L
Citation: W. Kalow et al., HYPOTHESIS - COMPARISONS OF INTERINDIVIDUAL AND INTRAINDIVIDUAL VARIATIONS CAN SUBSTITUTE FOR TWIN STUDIES IN DRUG RESEARCH, Pharmacogenetics, 8(4), 1998, pp. 283-289
Authors:
MASELLIS M
BASILE V
MELTZER HY
LIEBERMAN JA
SEVY S
MACCIARDI FM
COLA P
HOWARD A
BADRI F
NOTHEN MM
KALOW W
KENNEDY JL
Citation: M. Masellis et al., SEROTONIN SUBTYPE-2 RECEPTOR GENES AND CLINICAL-RESPONSE TO CLOZAPINEIN SCHIZOPHRENIA-PATIENTS, Neuropsychopharmacology, 19(2), 1998, pp. 123-132
Authors:
OZDEMIR V
NARANJO CA
SHULMAN RW
HERRMANN N
SELLERS EM
REED K
KALOW W
Citation: V. Ozdemir et al., DETERMINANTS OF INTERINDIVIDUAL VARIABILITY AND EXTENT OF CYP2D6 AND CYP1A2 INHIBITION BY PAROXETINE AND FLUVOXAMINE IN-VIVO, Journal of clinical psychopharmacology, 18(3), 1998, pp. 198-207
Authors:
OZDEMIR V
NARANJO CA
HERRMANN N
SHULMAN RW
SELLERS EM
REED K
KALOW W
Citation: V. Ozdemir et al., THE EXTENT AND DETERMINANTS OF CHANGES IN CYP2D6 AND CYP1A2 ACTIVITIES WITH THERAPEUTIC DOSES OF SERTRALINE, Journal of clinical psychopharmacology, 18(1), 1998, pp. 55-61
Authors:
MASELLIS M
BADRI F
MACCIARDI FM
MELTZER HY
LIEBERMAN JA
NOTHEN MM
HAMBLIN M
KALOW W
KENNEDY JL
Citation: M. Masellis et al., PHARMACOGENETIC ANALYSIS OF THE SEROTONIN SYSTEM AND RESPONSE TO CLOZAPINE, American journal of medical genetics, 74(6), 1997, pp. 612-613
Authors:
KALOW W
Citation: W. Kalow, PHARMACOGENETICS IN BIOLOGICAL PERSPECTIVE, Pharmacological reviews, 49(4), 1997, pp. 369-379
Authors:
RADYPENTEK P
MUELLER R
TANG BK
KALOW W
Citation: P. Radypentek et al., INTERINDIVIDUAL VARIATION IN THE ENZYMATIC 15-KETO-REDUCTION OF 13,14-DIHYDRO-15-KETO-PROSTAGLANDIN E-1 IN HUMAN LIVER AND IN HUMAN ERYTHROCYTES, European Journal of Clinical Pharmacology, 52(2), 1997, pp. 147-153
Authors:
KALOW W
KALANT H
Citation: W. Kalow et H. Kalant, EVOLUTIONARY PSYCHOLOGY - AN EXCHANGE( RESPONSE TO GOULD,STEPHEN,JAY ARTICLE ON DARWINIAN FUNDAMENTALISM ), The New York review of books, 44(15), 1997, pp. 56-56
Authors:
OZDEMIR V
NARANJO CA
HERRMANN N
REED K
SELLERS EM
KALOW W
Citation: V. Ozdemir et al., PAROXETINE POTENTIATES THE CENTRAL-NERVOUS-SYSTEM SIDE-EFFECTS OF PERPHENAZINE - CONTRIBUTION OF CYTOCHROME P4502D6 INHIBITION IN-VIVO, Clinical pharmacology and therapeutics, 62(3), 1997, pp. 334-347
Authors:
OZDEMIR V
NARANJO CA
HERRMANN N
SHULMAN RW
SELLERS EM
KALOW W
Citation: V. Ozdemir et al., SERTRALINE EFFECTS ON CYP1A2 AND CYP2D6 ISOZYME ACTIVITIES IN YOUNGERADULTS AND THE ELDERLY, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 46-46
Authors:
OZDEMIR V
NARANJO CA
SHULMAN RW
HERRMANN N
SELLERS EM
KALOW W
Citation: V. Ozdemir et al., AN IN-VIVO COMPARISON OF PAROXETINE AND FLUVOXAMINE - EFFECTS ON CYP1A2 AND CYP2D6 ACTIVITIES, Clinical pharmacology and therapeutics, 61(2), 1997, pp. 47-47
Authors:
PASTRAKULJIC A
TANG BK
ROBERTS EA
KALOW W
Citation: A. Pastrakuljic et al., DISTINCTION OF CYP1A1 AND CYP1A2 ACTIVITY BY SELECTIVE-INHIBITION USING FLUVOXAMINE AND ISOSAFROLE, Biochemical pharmacology, 53(4), 1997, pp. 531-538
Authors:
WU DF
OTTON SV
INABA T
KALOW W
SELLERS EM
Citation: Df. Wu et al., INTERACTIONS OF AMPHETAMINE ANALOGS WITH HUMAN LIVER CYP2D6, Biochemical pharmacology, 53(11), 1997, pp. 1605-1612
Authors:
TANG BK
KALOW W
Citation: Bk. Tang et W. Kalow, ANALYSIS OF WITHIN-SUBJECT VARIATION OF CAFFEINE METABOLISM WHEN USEDTO DETERMINE CYTOCHROME P4501A2 AND N-ACETYLTRANSFERASE-2 ACTIVITIES, Cancer epidemiology, biomarkers & prevention, 5(3), 1996, pp. 231-231
Authors:
APPANNA G
TANG BK
MULLER R
KALOW W
Citation: G. Appanna et al., A SENSITIVE METHOD FOR DETERMINATION OF CYTOCHROME P4502D6 ACTIVITY IN-VITRO USING BUPRANOLOL AS SUBSTRATE, Drug metabolism and disposition, 24(3), 1996, pp. 303-306
Authors:
OZDEMIR V
HERRMANN N
WALKER S
KALOW W
NARANJO CA
Citation: V. Ozdemir et al., PAROXETINE POTENTIATES CNS SIDE-EFFECTS OF PERPHENAZINE, Clinical pharmacology and therapeutics, 59(2), 1996, p.
Authors:
HALPERIN W
KALOW W
SWEENEY MH
TANG BK
FINGERHUT M
TIMPKINS B
WILLE K
Citation: W. Halperin et al., INDUCTION OF P-450 IN WORKERS EXPOSED TO DIOXIN, Occupational and environmental medicine, 52(2), 1995, pp. 86-91
Authors:
PATEL M
TANG BK
GRANT DM
KALOW W
Citation: M. Patel et al., INTERINDIVIDUAL VARIABILITY IN THE GLUCURONIDATION OF (S)-OXAZEPAM CONTRASTED WITH THAT OF (R)-OXAZEPAM, Pharmacogenetics, 5(5), 1995, pp. 287-297
Authors:
PATEL M
TANG BK
KALOW W
Citation: M. Patel et al., (S)OXAZEPAM GLUCURONIDATION IS INHIBITED BY KETOPROFEN AND OTHER SUBSTRATES OF UGT2B7, Pharmacogenetics, 5(1), 1995, pp. 43-49
Authors:
KALOW W
Citation: W. Kalow, LIFE OF A PHARMACOLOGIST OR THE RICH LIFE OF A POOR METABOLIZER, Pharmacology & toxicology, 76(4), 1995, pp. 221-227
Authors:
SCHADEL M
WU DA
OTTON SV
KALOW W
SELLERS EM
Citation: M. Schadel et al., PHARMACOKINETICS OF DEXTROMETHORPHAN AND METABOLITES IN HUMANS - INFLUENCE OF THE CYPBDB PHENOTYPE AND QUINIDINE INHIBITION, Journal of clinical psychopharmacology, 15(4), 1995, pp. 263-269
Authors:
TANG BK
KALOW W
Citation: Bk. Tang et W. Kalow, VARIABLE ACTIVATION OF LOVASTATIN BY HYDROLYTIC ENZYMES IN HUMAN PLASMA AND LIVER, European Journal of Clinical Pharmacology, 47(5), 1995, pp. 449-451
Authors:
WU DF
OTTON SV
KALOW W
SELLERS EM
Citation: Df. Wu et al., EFFECTS OF ROUTE OF ADMINISTRATION ON DEXTROMETHORPHAN PHARMACOKINETICS AND BEHAVIORAL-RESPONSE IN THE RAT, The Journal of pharmacology and experimental therapeutics, 274(3), 1995, pp. 1431-1437
Authors:
MASIMIREMBWA CM
BEKE M
HASLER JA
TANG BK
KALOW W
Citation: Cm. Masimirembwa et al., LOW CYP1A2 ACTIVITY IN RURAL SHONA CHILDREN OF ZIMBABWE, Clinical pharmacology and therapeutics, 57(1), 1995, pp. 25-31
Authors:
LLEWELLYN BE
KALOW W
TANG BK
PANDYA A
SCHIEKEN RM
MEYER JM
NANCE WE
Citation: Be. Llewellyn et al., EFFECT OF PASSIVE SMOKING ON CYP1A2 ACTIVITY IN TWINS, American journal of human genetics, 57(4), 1995, pp. 1843-1843